Often, once injections start, patients discontinue separate oral B supplements, sticking to perhaps just a basic multivitamin or prenatal vitamin at most
Where Do Related Products Fit in Category Mapping
We dont know if chronic use impacts hormones, sleep architecture, or neurological health
Song E, Su C, Fu J, Xia X, Yang S, Xiao C et al
Andrea Corona MapLight reports mixed results in Schizophrenia trial In their Phase 2 ZEPHR trial, MapLights novel oral drug for schizophrenia, the Ml/M4 muscarinic agonist ML-007C-MA, successfully hit its primary endpoint but only for the twice-daily version, not the once-daily dose
Headache: The most commonly reported adverse event was headache, characterized as mild to moderate in severity